APOE and Alzheimer disease: For example, in our previous work (Sapkota et al., 2015, 2017; Sapkota and Dixon, 2018), we established an AD-genetic risk score (AD-GRS; Clusterin [CLU; rs11136000] + Complement receptor 1 [CR1; rs6656401] + Phosphatidylinositol binding clathrin assembly protein [PICALM; rs3851179]) and a cognitive aging genetic risk score that influences executive function (EF) performance and change as modified by APOE (rs7412, rs4293580) in non-demented older adults.